Читать книгу Neurology - Charles H. Clarke - Страница 82

Anti‐CD20 and anti‐CD52 monoclonal antibodies are increasingly used, sometimes in combination with other immunosuppressants such as rituximab or methotrexate. Idiosyncratic rare complications are limiting factors. For example, PML (progressive multifocal leukoencephalopathy) is a known, usually fatal complication of rituximab, natalizumab and others. When death or severe disability is not an outcome of the primary disease, these medications are ethically questionable.